Corbus Pharmaceuticals
CRBP
88 hedge funds and large institutions have $150M invested in Corbus Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 7 closing their positions.
286% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 7
106% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 16
38% more capital invested
Capital invested by funds: $109M → $150M (+$41.1M)
28% more funds holding
Funds holding: 69 → 88 (+19)
0.27% more ownership
Funds ownership: 1.01% → 1.28% (+0.27%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
81% less call options, than puts
Call options by funds: $263K | Put options by funds: $1.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.63M |
| 2 |
BlackRock
New York
|
+$7.11M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$4.71M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.28M |
| 5 |
Morgan Stanley
New York
|
+$3.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.11M |
| 2 |
PA
Perceptive Advisors
New York
|
-$1.53M |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
-$354K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$245K |
| 5 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$179K |
CRBP Hedge Fund Activity: Q4 2017 in Review
88 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2017, worth a combined $150M — up 38% from $109M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CRBP positions and 7 closed out — a net gain of 20 holders — while 33 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $9.63M. The largest seller was Millennium Management, cutting an estimated $2.11M.
- 88 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2017, up from 69 in Q3 2017.
- Funds reported $150M of Corbus Pharmaceuticals stock for Q4 2017, up 38% quarter-over-quarter.
- 27 funds opened new Corbus Pharmaceuticals positions in Q4 2017 and 7 closed out, a net change of +20 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2017 was Fidelity Investments, an estimated $9.63M added.
- The largest Corbus Pharmaceuticals seller in Q4 2017 was Millennium Management, an estimated $2.11M sold.
Based on aggregated 13F filings for Q4 2017.